Research Projects

XPRIME. Exploring and exploiting cross-priming in cancer immunotherapy

Dr. Álvaro Teijeira Sánchez

Project information

XPRIME seeks to identify the dynamic roles of cDC1s in modulating CD8+ T cell responses during immunotherapy using acute depletion schemes, in vivo imaging techniques, and human cancer samples. We will study the role of PD-L1 expressed in this particular subset of dendritic cells as a potential target for immune checkpoint-based immunotherapy and define its limitations in antigen cross-priming. This is an R&D led by Dr Álvaro Teijeira, a researcher at the Immunology and Immunotherapy Program.

  • Convocation: FIMA 2022 LAB AECC 
  • Reference: LABAE222982TEIJ
  • Start date: December 1, 2022
  • End date: November 30, 2025
  • Funder: Asociación Española contra el Cáncer
  • Nature of project: National
  • Award year 2022

Need more information?

If you are interested in learning more about our research, please contact us